This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción GBI1
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de Genocea Biosciences, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.052 |
| 52 Week High | US$1.77 |
| 52 Week Low | US$0.046 |
| Beta | 1.95 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -96.92% |
| 3 Year Change | -98.32% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.92% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| GBI1 | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 0% | 2.1% | -1.0% |
| 1Y | -96.9% | -22.4% | 2.0% |
Rentabilidad vs. Industria: GBI1 underperformed the German Biotechs industry which returned -3.1% over the past year.
Rentabilidad vs. Mercado: GBI1 underperformed the German Market which returned -23.5% over the past year.
Volatilidad de los precios
| GBI1 volatility | |
|---|---|
| GBI1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: GBI1 has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine GBI1's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2006 | 74 | Chip Clark | www.genocea.com |
Resumen de fundamentos de Genocea Biosciences, Inc.
| Estadísticas fundamentales de GBI1 | |
|---|---|
| Capitalización bursátil | €655.74k |
| Beneficios(TTM) | -€37.04m |
| Ingresos (TTM) | €1.90m |
0.3x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está GBI1 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de GBI1 | |
|---|---|
| Ingresos | US$1.91m |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$1.91m |
| Otros gastos | US$39.10m |
| Beneficios | -US$37.19m |
Últimos beneficios comunicados
Mar 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.63 |
| Margen bruto | 100.00% |
| Margen de beneficio neto | -1,946.15% |
| Ratio deuda/patrimonio | 61.7% |
¿Cómo se ha desempeñado GBI1 a largo plazo?
Ver rendimiento histórico y comparativa